Drug Profile

CXR 102

Alternative Names: CXR-102

Latest Information Update: 01 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CorriXR Therapeutics
Class Antineoplastics; Gene therapies
Mechanism of Action Gene silencing

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Non-small cell lung cancer

Most Recent Events

17 Nov 2025 Pharmacodynamics data from preclinical studies in Non small cell lung cancer released by CorriXR Therapeutics
05 Sep 2025 Preclinical trials in Non-small cell lung cancer in USA (Intratumoural), before September 2025 (CorriXR Therapeutics pipeline, September 2025)
19 Aug 2025 CorriXR Therapeutics has patent protection for non-viral gene editing platform

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com